Table 1. Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021

Always make recommendations by determining needed vaccines based on age (Table 1), determining appropriate intervals for catch-up, if needed (Table 2), assessing for medical indications (Table 3), and reviewing special situations (Notes).

COVID-19 Vaccination

ACIP recommends use of COVID-19 vaccines for everyone ages 5 and older within the scope of the Emergency Use Authorization or Biologics License Application for the particular vaccine. COVID-19 vaccine and other vaccines may be administered on the same day. See the COVID-19 Vaccine Product Information page for additional information about COVID-19 vaccines authorized for use in the United States.

Legend

Range of recommended ages for all children

Range of recommended ages for catch-up immunization

Range of recommended ages for certain high-risk groups

Recommended based on shared clinical decision-making or
*can be used in this age group

No recommendation/Not applicable

Birth to 15 Months

child vaccine schedule table 1
Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos
Hepatitis B more info icon. (HepB) 1st dose ←2nd dose→ ←3rd dose→
Rotavirus more info icon.
(RV) RV1 (2-dose series); RV5 (3-dose series)
1st dose 2nd dose See notes
Diphtheria, tetanus, & acellular pertussis more info icon.
(DTaP: <7 yrs)
1st dose 2nd dose 3rd dose ←4th dose→
Haemophilus influenzae type b more info icon.
(Hib)
1st dose 2nd dose See notes ←3rd or 4th dose,
See notes
Pneumococcal conjugate more info icon.
(PCV13)
1st dose 2nd dose 3rd dose ←4th dose→
Inactivated poliovirus more info icon.
(IPV: <18 yrs)
1st dose 2nd dose ←3rd dose→
Influenza (IIV) more info icon. Annual vaccination 1 or 2 doses
more info icon.
Influenza (LAIV4) more info icon.
Measles, mumps, rubella more info icon.
(MMR)
See notes ←1st dose→
Varicella more info icon.
(VAR)
←1st dose→
Hepatitis A more info icon.
(HepA)
See notes ←2-dose series, See notes
Tetanus, diphtheria, & acellular pertussis more info icon.
(Tdap: ≥7 yrs)
Human papillomavirus more info icon.
(HPV)
Meningococcal more info icon.
(MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
See notes
Meningococcal B more info icon. (MenB)
Pneumococcal polysaccharide more info icon.
(PPSV23)

18 Months to 18 Years

child vaccine schedule table 2
Vaccines 18 mos 19-23 mos 2-3 yrs 4-6 yrs 7-10 yrs 11-12 yrs 13-15 yrs 16 yrs 17-18 yrs
Hepatitis B more info icon.
(HepB)
←3rd dose→
Rotavirus more info icon.
(RV) RV1 (2-dose series); RV5 (3-dose series)
Diphtheria, tetanus, & acellular pertussis more info icon.
(DTaP: <7 yrs)
←4th dose→ 5th dose
Haemophilus influenzae type b more info icon.
(Hib)
Pneumococcal conjugate more info icon.
(PCV13)
Inactivated poliovirus more info icon.
(IPV: <18 yrs)
←3rd dose→ 4th dose
Influenza (IIV) more info icon. Annual vaccination 1 or 2 doses Annual vaccination 1 dose only
more info icon.
Influenza (LAIV4) more info icon.
more info icon.
Annual vaccination 1 or 2 doses
Annual vaccination 1 dose only
Measles, mumps, rubella more info icon.
(MMR)
2nd dose
Varicella more info icon.
(VAR)
2nd dose
Hepatitis A more info icon.
(HepA)
← 2-dose series, See notes
Tetanus, diphtheria, & acellular pertussis more info icon.
(Tdap: ≥7 yrs)
Tdap
Human papillomavirus more info icon.
(HPV)
See notes
*
Meningococcal more info icon.
(MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)
See notes 1st dose 2nd dose
Meningococcal B more info icon.
(MenB)
See notes
Pneumococcal polysaccharide more info icon.
(PPSV23)
See notes

Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Notes

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021

For vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2021.

Additional information

COVID-19 Vaccination

ACIP recommends use of COVID-19 vaccines for everyone ages 5 and older within the scope of the Emergency Use Authorization or Biologics License Application for the particular vaccine. COVID-19 vaccine and other vaccines may be administered on the same day. See the COVID-19 Vaccine Product Information page for additional information about COVID-19 vaccines authorized for use in the United States.

  • Consult relevant ACIP statements for detailed recommendations.
  • For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization and relevant ACIP statements.
  • For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
  • Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
  • Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization.
  • Information on travel vaccination requirements and recommendations is available at https://www.cdc.gov/travel/.
  • For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization, and Immunization in Special Clinical Circumstances (In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics, 2018:67–111).
  • For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
  • The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information, see www.hrsa.gov/vaccinecompensation/index.htmlexternal icon.

Diphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks [4 years for Kinrix or Quadracel])

Routine vaccination

  • 5-dose series at 2, 4, 6, 15–18 months, 4–6 years
    • Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
    • Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3.

Catch-up vaccination

  • Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
  • For other catch-up guidance, see Table 2.

Special situations

  • Wound management in children less than age 7 years with history of 3 or more doses of tetanus-toxoid-containing vaccine: For all wounds except clean and minor wounds, administer DTaP if more than 5 years since last dose of tetanus-toxoid-containing vaccine. For detailed information, see www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm.

Haemophilus influenzae type b vaccination
(minimum age: 6 weeks)

Routine vaccination

  •  ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 6, 12–15 months
  •  PedvaxHIB: 3-dose series at 2, 4, 12–15 months

Catch-up vaccination

  • Dose 1 at age 711 months: Administer dose 2 at least 4 weeks later and dose 3 (final dose) at age 12–15 months or 8 weeks after dose 2 (whichever is later).
  • Dose 1 at age 1214 months: Administer dose 2 (final dose) at least 8 weeks after dose 1.
  • Dose 1 before age 12 months and dose 2 before age 15 months: Administer dose 3 (final dose) 8 weeks after dose 2.
  • 2 doses of PedvaxHIB before age 12 months: Administer dose 3 (final dose) at age 12–59 months and at least 8 weeks after dose 2.
  • 1 dose administered at age 15 months or older: No further doses needed
  • Unvaccinated at age 15–59 months: Administer 1 dose.
  • Previously unvaccinated children age 60 months or older who are not considered high risk: Do not require catch-up vaccination
  • For other catch-up guidance, see Table 2.

Special situations

  • Chemotherapy or radiation treatment:
    12–59 months
    • Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
    • 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

    Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion.

  • Hematopoietic stem cell transplant (HSCT):
    • 3-dose series 4 weeks apart starting 6 to 12 months after successful transplant regardless of Hib vaccination history
  • Anatomic or functional asplenia (including sickle cell disease):
    12–59 months
    • Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
    • 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
    Unvaccinated* persons age 5 years or older
    • 1 dose
  • Elective splenectomy:
    Unvaccinated* persons age 15 months or older
    • 1 dose (preferably at least 14 days before procedure)
  • HIV infection:
    12–59 months
    • Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
    • 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
    Unvaccinated* persons age 5–18 years
    • 1 dose
  • Immunoglobulin deficiency, early component complement deficiency:
    12–59 months
    • Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
    • 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

*Unvaccinated = Less than routine series (through age 14 months) OR no doses (age 15 months or older)

Hepatitis A vaccination
(minimum age: 12 months for routine vaccination)

Routine vaccination

  • 2-dose series (minimum interval: 6 months) beginning at age
    12 months

Catch-up vaccination

  • Unvaccinated persons through age 18 years should complete a 2-dose series (minimum interval: 6 months).
  • Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.
  • Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, Twinrix®, as a 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).

International travel

  • Persons traveling to or working in countries with high or intermediate endemic hepatitis A
    (http://www.cdc.gov/travel/)
    • Infants age 611 months: 1 dose before departure; revaccinate with 2 doses, separated by at least 6 months, between age 12–23 months.
    • Unvaccinated age 12 months or  older: Administer dose 1 as soon as travel is considered.

Hepatitis B vaccination (minimum age: birth)

Birth dose (monovalent HepB vaccine only)

  • Mother is HBsAg-negative: 1 dose within 24 hours of birth for all medically stable infants ≥2,000 grams. Infants <2,000 grams: Administer 1 dose at chronological age 1 month or hospital discharge (whichever is earlier and even if weight is still <2,000 grams).
  • Mother is HBsAg-positive:
    • Administer HepB vaccine and hepatitis B immune globulin (HBIG) (in separate limbs) within 12 hours of birth, regardless of birth weight. For infants <2,000 grams, administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
    • Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose.
  • Mother’s HBsAg status is unknown:
    • Administer HepB vaccine within 12 hours of birth, regardless of birth weight.
    • For infants <2,000 grams, administer HBIG in addition to HepB vaccine (in separate limbs) within 12 hours of birth. Administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
    • Determine mother’s HBsAg status as soon as possible. If mother is HBsAg-positive, administer HBIG to infants ≥2,000 grams as soon as possible, but no later than 7 days of age.

Routine series

  • 3-dose series at 0, 1–2, 6–18 months (use monovalent HepB vaccine for doses administered before age 6 weeks)
  • Infants who did not receive a birth dose should begin the series as soon as feasible (see Table 2).
  • Administration of 4 doses is permitted when a combination vaccine containing HepB is used after the birth dose.
  • Minimum age for the final (3rd or 4th ) dose: 24 weeks
  • Minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 8 weeks / dose 1 to dose 3: 16 weeks (when 4 doses are administered, substitute “dose 4” for “dose 3” in these calculations)

Catch-up vaccination

  • Unvaccinated persons should complete a 3-dose series at 0, 1–2, 6 months.
  • Adolescents age 11–15 years may use an alternative 2-dose schedule with at least 4 months between doses (adult formulation Recombivax HB only).
  • Adolescents age 18 years or older may receive a 2-dose series of HepB (Heplisav-B®) at least 4 weeks apart.
  • Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, Twinrix, as a 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months).
  • For other catch-up guidance, see Table 2.

Special situations

  • Revaccination is not generally recommended for persons with a normal immune status who were vaccinated as infants, children, adolescents, or adults.
  • Revaccination may be recommended for certain populations, including:
    • Infants born to HBsAg-positive mothers
    • Hemodialysis patients
    • Other immunocompromised persons
  • For detailed revaccination recommendations, see http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html.

Human papillomavirus vaccination (minimum age: 9 years)

Routine and catch-up vaccination

  • HPV vaccination routinely recommended at age 11–12 years (can start at age 9 years) and catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated
  • 2- or 3-dose series depending on age at initial vaccination:
    • Age 9 –14 years at initial vaccination: 2-dose series at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon)
    • Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2 months, 6 months (minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 3: 5 months; repeat dose if administered too soon)
  • Interrupted schedules: If vaccination schedule is interrupted, the series does not need to be restarted.
  • No additional dose recommended after completing series with recommended dosing intervals using any HPV vaccine.

Special situations

  • Immunocompromising conditions, including HIV infection: 3-dose series as above
  • History of sexual abuse or assault: Start at age 9 years.
  • Pregnancy: HPV vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination

Influenza vaccination (minimum age: 6 months [IIV], 2 years [LAIV4], 18 years [recombinant influenza vaccine, RIV4])

Routine vaccination

  • Use any influenza vaccine appropriate for age and health status annually:
    • 2 doses, separated by at least 4 weeks, for children age 6 months–8 years who have received fewer than 2 influenza vaccine doses before July 1, 2020, or whose influenza vaccination history is unknown (administer dose 2 even if the child turns 9 between receipt of dose 1 and dose 2)
    • 1 dose for children age 6 months–8 years who have received at least 2 influenza vaccine doses before July 1, 2020
    • 1 dose for all persons age 9 years or older
  • For the 2021–22 season, see the 2021–22 ACIP influenza vaccine recommendations.

Special situations

  • Egg allergy, hives only: Any influenza vaccine appropriate for age and health status annually
  • Egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress, need for emergency medical services or epinephrine): Any influenza vaccine appropriate for age and health status annually. If using an influenza vaccine other than Flublok or Flucelvax, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions.
  • Severe allergic reactions to vaccines can occur even in the absence of a history of previous allergic reaction. All vaccination providers should be familiar with the office emergency plan and certified in cardiopulmonary resuscitation.
  • A previous severe allergic reaction to influenza vaccine is a contraindication to future receipt of any influenza vaccine.
  • LAIV4 should not be used in persons with the following conditions or situations:
    • History of severe allergic reaction to a previous dose of any influenza vaccine or to any vaccine component (excluding egg, see details above)
    • Receiving aspirin or salicylate-containing medications
    • Age 2–4 years with history of asthma or wheezing
    • Immunocompromised due to any cause (including medications and HIV infection)
    • Anatomic or functional asplenia
    • Close contacts or caregivers of severely immunosuppressed persons who require a protected environment
    • Pregnancy
    • Cochlear implant
    • Cerebrospinal fluid-oropharyngeal communication
    • Children less than age 2 years
    • Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days

Measles, mumps, and rubella vaccination (minimum age: 12 months for routine vaccination)

Routine vaccination

  • 2-dose series at 12–15 months, 4–6 years
  • Dose 2 may be administered as early as 4 weeks after dose 1.

Catch-up vaccination

  • Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart
  • The maximum age for use of MMRV is 12 years.

Special situations

International travel

  • Infants age 611 months: 1 dose before departure; revaccinate with 2-dose series at age 12–15 months (12 months for children in high-risk areas) and dose 2 as early as 4 weeks later.
  • Unvaccinated children age 12 months or older: 2-dose series at least 4 weeks apart before departure

Meningococcal serogroup A, C, W, Y vaccination (minimum age: 2 months [MenACWY-CRM, Menveo], 9 months [MenACWY-D, Menactra], 2 years [MenACWY-TT, MenQuadfi])

Routine vaccination

  • 2-dose series at 11–12 years, 16 years

Catch-up vaccination

  • Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks)
  • Age 16–18 years: 1 dose

Special situations

Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:

  • Menveo
    • Dose 1 at age 8 weeks: 4-dose series at 2, 4, 6, 12 months
    • Dose 1 at age 3–6 months: 3- or 4- dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
    • Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
    • Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart
  • Menactra
    • Persistent complement component deficiency or complement inhibitor use:
      • Age 9–23 months: 2-dose series at least 12 weeks apart
      • Age 24 months or older: 2-dose series at least 8 weeks apart
    • Anatomic or functional asplenia, sickle cell disease, or HIV infection:
      • Age 9–23 months: Not recommended
      • Age 24 months or older: 2-dose series at least 8 weeks apart
      • Menactra must be administered at least 4 weeks after completion of PCV13 series.
  • MenQuadfi
    • Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart

Travel in countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj
(http://www.cdc.gov/travel/):

  • Children age less than 24 months:
    • Menveo (age 2–23 months)
      • Dose 1 at age 8 weeks: 4-dose series at 2, 4, 6, 12 months
      • Dose 1 at age 3–6 months: 3- or 4- dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
      • Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
    • Menactra (age 9–23 months)
      • 2-dose series (dose 2 at least 12 weeks after dose 1; dose 2 may be administered as early as 8 weeks after dose 1 in travelers)
  • Children age 2 years or older: 1 dose Menveo, Menactra, or MenQuadfi

First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) or military recruits:

  • 1 dose Menveo, Menactra, or MenQuadfi

Adolescent vaccination of children who received MenACWY prior to age 10 years:

  • Children for whom boosters are recommended because of an ongoing increased risk of meningococcal disease (e.g., those with complement deficiency, HIV, or asplenia): Follow the booster schedule for persons at increased risk.
  • Children for whom boosters are not recommended (e.g., a healthy child who received a single dose for travel to a country where meningococcal disease is endemic): Administer MenACWY according to the recommended adolescent schedule with dose 1 at age 11–12 years and dose 2 at age 16 years.

Note: Menactra should be administered either before or at the same time as DTaP. For MenACWY booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and  additional meningococcal vaccination information, see https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

Meningococcal serogroup B vaccination (minimum age: 10 years [MenB-4C, Bexsero; MenB-FHbp, Trumenba])

Shared Clinical Decision-Making

  • Adolescents not at increased risk age 16–23 years (preferred age 16–18 years) based on shared clinical decision-making:
    • Bexsero: 2-dose series at least 1 month apart
    • Trumenba: 2-dose series at least 6 months apart; if dose 2 is administered earlier than 6 months, administer a 3rd dose at least 4 months after dose 2.

Special situations

Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:

  • Bexsero: 2-dose series at least 1 month apart
  • Trumenba: 3-dose series at 0, 1–2, 6 months

Bexsero and Trumenba are not interchangeable; the same product should be used for all doses in a series. For MenB booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and additional meningococcal vaccination information, see https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

Pneumococcal vaccination (minimum age: 6 weeks [PCV13], 2 years [PPSV23])

Routine vaccination with PCV13

  • 4-dose series at 2, 4, 6, 12–15 months

Catch-up vaccination with PCV13

  • 1 dose for healthy children age 24–59 months with any incomplete* PCV13 series
  • For other catch-up guidance, see Table 2.

Special situations

Underlying conditions below: When both PCV13 and PPSV23 are indicated, administer PCV13 first. PCV13 and PPSV23 should not be administered during same visit. Chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma treated with high-dose, oral corticosteroids); diabetes mellitus:

Age 2–5 years
  • Any incomplete* series with:
    • 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
    • Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
  • No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after completing all recommended PCV13 doses)
Age 6–18 years
  • No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after completing all recommended PCV13 doses)

Cerebrospinal fluid leak, cochlear implant:

Age 2–5 years
  • Any incomplete* series with:
    • 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
    • Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
  • No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)
Age 6–18 years
  • No history of either PCV13 or PPSV23: 1 dose PCV13, 1 dose PPSV23 at least 8 weeks later
  • Any PCV13 but no PPSV23: 1 dose PPSV23 at least 8 weeks after the most recent dose of PCV13
  • PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent dose of PPSV23

Sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma:

Age 2–5 years
  • Any incomplete* series with:
    • 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose)
    • Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
  • No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose) and a 2nd dose of PPSV23 5 years later
Age 6–18 years
  • No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)
  • Any PCV13 but no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after the most recent dose of PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23)
  • PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent PPSV23 dose and a 2nd dose of PPSV23 administered 5 years after dose 1 of PPSV23 and at least 8 weeks after a dose of PCV13

Chronic liver disease, alcoholism:

Age 6–18 years
  • No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose)

*Incomplete series = Not having received all doses in either the recommended series or an age-appropriate catch-up series. See Tables 8, 9, and 11 in the in the ACIP pneumococcal vaccine recommendations (https://www.cdc.gov/mmwr/pdf/rr/rr5911.pdfpdf icon) for complete schedule details.

Poliovirus vaccination (minimum age: 6 weeks)

Routine vaccination

  • 4-dose series at ages 2, 4, 6–18 months, 4–6 years; administer the final dose on or after age 4 years and at least 6 months after the previous dose.
  • 4 or more doses of IPV can be administered before age 4 years when a combination vaccine containing IPV is used. However, a dose is still recommended on or after age 4 years and at least 6 months after the previous dose.

Catch-up vaccination

  • In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
  • IPV is not routinely recommended for U.S. residents age 18 years or older.

Series containing oral polio vaccine (OPV), either mixed OPV-IPV or OPV-only series:

  • Total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. See https://www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm.
  • Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements.
    • Doses of OPV administered before April 1, 2016, should be counted (unless specifically noted as administered during a campaign).
    • Doses of OPV administered on or after April 1, 2016, should not be counted.
      For guidance to assess doses documented as “OPV,” see http://www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm.
  • For other catch-up guidance, see Table 2.

Rotavirus vaccination (minimum age: 6 weeks)

Routine vaccination

  • Rotarix: 2-dose series at 2 and 4 months
  • RotaTeq: 3-dose series at 2, 4, and 6 months
  • If any dose in the series is either RotaTeq or unknown, default to 3-dose series.

Catch-up vaccination

  • Do not start the series on or after age 15 weeks, 0 days.
  • The maximum age for the final dose is 8 months, 0 days.
  • For other catch-up guidance, see Table 2.

Tetanus, diphtheria, and pertussis (Tdap) vaccination (minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination)

Routine vaccination

  • Adolescents age 11–12 years: 1 dose Tdap
  • Pregnancy: 1 dose Tdap during each pregnancy, preferably during the early part of gestational weeks 27–36
  • Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.

Catch-up vaccination

  • Adolescents age 13–18 years who have not received Tdap: 1 dose Tdap, then Td or Tdap booster every 10 years
  • Persons age 7–18 years not fully vaccinated* with DTaP: 1 dose Tdap as part of the catch-up series (preferably the first dose); if additional doses are needed, use Td or Tdap.
  • Tdap administered at age 7–10 years
    • Children age 7–9 years who receive Tdap should receive the routine Tdap dose at age 11–12 years.
    • Children age 10 years who receive Tdap do not need  the routine Tdap dose at age 11–12 years.
  • DTaP inadvertently administered  on or after age 7 years:
    • Children age 7–9 years: DTaP may count as part of catch-up series. Administer routine Tdap dose at age 11–12 years.
    • Children age 10–18 years: Count dose of DTaP as the adolescent Tdap booster.
  • For other catch-up guidance, see Table 2.

Special situations

  • Wound management in persons age 7 years or older with history of 3 or more doses of tetanus-toxoid-containing vaccine: For clean and minor wounds, administer Tdap or Td if more than 10 years since last dose of tetanus-toxoid-containing vaccine; for all other wounds, administer Tdap or Td if more than 5 years since last dose of tetanus-toxoid-containing vaccine. Tdap is preferred for persons age 11 years or older who have not previously received Tdap or whose Tdap history is unknown. If a tetanus-toxoid-containing vaccine is indicated for a pregnant adolescent, use Tdap. For detailed information, see https://www.cdc.gov/mmwr/volumes/69/wr/mm6903a5.htm.

*Fully vaccinated = 5 valid doses of DTaP OR 4 valid doses of DTaP if dose 4 was administered at age 4 years or older.

Varicella vaccination (minimum age: 12 months)

Routine vaccination

  • 2-dose series at 12–15 months, 4–6 years
  • Dose 2 may be administered as early as 3 months after dose 1 (a dose administered after a 4-week interval may be counted).

Catch-up vaccination

  • Ensure persons age 7–18 years without evidence of immunity (see MMWR at http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdfpdf icon ) have a 2-dose series:
    • Age 7–12 years: routine interval: 3 months (a dose administered after a 4-week interval may be counted)
    • Age 13 years or older: routine interval: 4–8 weeks (minimum interval: 4 weeks)
    • The maximum age for use of MMRV is 12 years.

Vaccines in the Child and Adolescent Immunization Schedule

child acronyms
Vaccines Abbreviations Trade Names
Diphtheria, tetanus, and acellular pertussis vaccine DTaP Daptacel®
Infanrix®
Diphtheria, tetanus vaccine DT No Trade Name
Haemophilus influenzae type B vaccine Hib (PRP-T)
Hib (PRP-OMP)
ActHIB®
Hiberix®
PedvaxHIB®
Hepatitis A vaccine HepA Havrix®
Vaqta®
Hepatitis B vaccine HepB Engerix-B®
Recombivax HB®
Human papillomavirus vaccine HPV Gardasil 9®
Influenza vaccine (inactivated) IIV Multiple
Influenza vaccine (live, attenuated) LAIV4 FluMist® Quadrivalent
Measles, mumps, and rubella vaccine MMR M-M-R® II
Meningococcal serogroups A, C, W, Y vaccine MenACWY-D
MenACWY-CRM
MenACWY-TT
Menactra®
Menveo®
MenQuadfi®
Meningococcal serogroup B vaccine MenB-4C
MenB-FHbp
Bexsero®
Trumenba®
Pneumococcal 13-valent conjugate vaccine PCV13 Prevnar 13®
Pneumococcal 23-valent polysaccharide vaccine PPSV23 Pneumovax® 23
Poliovirus vaccine (inactivated) IPV IPOL®
Rotavirus vaccine RV1
RV5
Rotarix®
RotaTeq®
Tetanus, diphtheria, and acellular pertussis vaccine Tdap Adacel®
Boostrix®
Tetanus and diphtheria vaccine Td Tenivac®
TDvax™
Varicella vaccine VAR Varivax®

Combination Vaccines

(Use combination vaccines instead of separate injections when appropriate)

Vaccines Abbreviations Trade Names
DTaP, hepatitis B, and inactivated poliovirus vaccine DTaP-HepB-IPV Pediarix®
DTaP, inactivated poliovirus, and Haemophilus influenzae type B vaccine DTaP-IPV/Hib Pentacel®
DTaP and inactivated poliovirus vaccine DTaP-IPV Kinrix®
Quadracel®
DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine DTaP-IPV-Hib-HepB Vaxelis®
Measles, mumps, rubella, and varicella vaccines MMRV ProQuad®
This schedule is recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAPexternal icon), American Academy of Family Physicians (AAFPexternal icon)), American College of Obstetricians and Gynecologists (ACOGexternal icon), American College of Nurse-Midwives (ACNMexternal icon), American Academy of Physician Assistants (AAPAexternal icon), and National Association of Pediatric Nurse Practitioners (NAPNAPexternal icon).
The comprehensive summary of the ACIP recommended changes made to the child and adolescent immunization schedule can be found in the February 12, 2021 MMWR.

Report

  • Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
  • Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.govexternal icon or (800-822-7967)

Helpful information

Page last reviewed: February 12, 2021